Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice.

Galafold (migalastat) - Amicus

Elfabrio (pegunigalsidase alfa-iwxj) - Protalix, Chiesi

Fabrazyme (agalsidase beta) - Sanofi

Replagal (agalsidase alfa) - Samaritan Pharma, Takeda

http://www.ncbi.nlm.nih.gov/pubmed/39636569

Antonino Tuttolomondo; Antonio Pisani; Elena Biagini; Federico Pieruzzi; Maurizio Pieroni; Renzo Mignani; Vittoria Cianci

Dec 5, 2024